The CATIE Schizophrenia Trial is part of the Clinical Antipsychotic Trials of Intervention
Effectiveness (CATIE) Project. The schizophrenia trial is being conducted to determine the
long-term effects and usefulness of antipsychotic medications in persons with schizophrenia.
It is designed for people with schizophrenia who may benefit from a medication change. The
study involves the newer atypical antipsychotics (olanzapine, quetiapine, risperidone,
clozapine, and ziprasidone)and the typical antipsychotics (perphenazine and fluphenazine
decanoate). All participants will receive an initial comprehensive medical and psychiatric
evaluation and will be closely followed throughout the study. For most participants the study
will last up to 18 months. Everyone in the study will be offered an educational program about
schizophrenia and family members will be encouraged to participate.
We are doing this research study to evaluate the effectiveness and safety of fluphenazine
decanoate when injected with a needle into psoriasis lesions in adults. Fluphenazine
decanoate is FDA (U.S. Food and Drug Administration) approved for use in people who have
schizophrenia and psychotic symptoms. Fluphenazine decanoate is not approved by the FDA for
use in psoriasis. Fluphenazine decanoate slows T cell growth in cells in laboratory test
tubes. Its usefulness and safety in people with psoriasis will be investigated in this study.
We are doing this research study to evaluate the effectiveness and safety of fluphenazine
decanoate when injected with a needle into psoriasis lesions in adults. Fluphenazine
decanoate is FDA (U.S. Food and Drug Administration) approved for use in people who have
schizophrenia and psychotic symptoms. Fluphenazine decanoate is not approved by the FDA for
use in psoriasis. Fluphenazine decanoate slows T cell growth in cells in laboratory test
tubes. Its usefulness and safety in people with psoriasis will be investigated in this study.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
